Composition :
Ergotika 1 mg contains Co-dergocrine mesylate 1 mg/tablet.
Ergotika 4.5 mg contains Co-dergocrine mesylate 4.5 mg/tablet enteric coated.
Ergotika injection contains Co-dergocrine mesylate 0.3 mg/ml.
Indications :
Symptoms and signs of mental deterioration notably those related to aging: dizziness, headache, poor concentration, disorientation, impaired memory, unsociability, difficulties with daily living activities and with self-care.
Dosage :
- Parenteral :
For acute cerebrovascular disorders the drug is first administered parenterally, this is then followed by oral therapy. The dose is 0.3 mg (1 ml) administered as i.v. drip or slow i.v. injection (in 20 ml dextrose or saline) once or twice daily alternatively, 0.3 mg (1 ml) may be given intramuscularly or subcutaneously once to several times daily.
- Oral :
1 Ergotika 4.5 mg tablet preferably before breakfast or 1 to 2 mg, three times daily, unless otherwise prescribed by the physician.
Adverse reactions :
No serious side efects have been reported. Occasionally undesired effects can occur, such as nausea, gastric upset, skin eruptions, congestion of the nasal mucous membrane and orthostatic hypotension. In the majority of cases side effects disappear without specific measure being taken.
Presentation :
ERGOTIKA 1 mg tablets : Boxes of 10 strips of 10 tablets.
ERGOTIKA 4.5 mg tablets : Boxes of 3 strips of 10 tablets enteric coated.
ERGOTIKA 0.3 mg injections : Boxes of 10 ampoules of 1 ml.
Reg. No. D 7813023
Reg. No. DKL 9009304610A1
Reg. No. DKL 9409309343A1 |
